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ABSTRACT 
Signal Transducer and Activator of Transcription 3 (STAT3) has been tied to 
various physiological and pathological functions, mainly as a transcription factor that 
translocates to the nucleus upon tyrosine phosphorylation induced by cytokine 
stimulation. In addition, a small pool of STAT3 resides in the mitochondria where it 
serves as a sensor for various metabolic stressors including reactive oxygen species 
(ROS).  Mitochondrially-localized STAT3 largely exerts its effects through direct or 
indirect regulation of the activity of the electron transport chain (ETC).  It has been 
assumed that STAT3 amounts in the mitochondria are static. We showed that various 
stimuli, including oxidative stress and cytokines, triggered a signaling cascade that 
resulted in a rapid loss of mitochondrially-localized STAT3.  Recovery of the 
mitochondrial pool of STAT3 over time depended upon phosphorylation of Ser727 in 
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STAT3 and new protein synthesis. Under these conditions, mitochondrially-localized 
STAT3 also became competent to bind to cyclophilin D (CypD).   Binding of STAT3 to 
CypD was mediated by the N-terminus of STAT3, which was also important for reducing 
mitochondrial ROS production after oxidative stress. These results outline a role for 
mitochondrially-localized STAT3 in sensing and responding to external stimuli.  
  
INTRODUCTION 
Signal Transducer and Activator of Transcription 3 (STAT3), a member of the 
STAT family of nuclear transcription factors, plays a key role in the regulation of a 
diverse set of physiological processes.  Ideally situated as a molecular link between 
cellular inputs and nuclear gene regulation, STAT3 is aberrantly regulated under various 
pathological conditions including cancer, cardiovascular disease, and disorders in 
immune responses.  The intricacies of this signaling network have been teased out to 
better appreciate the mechanisms behind STAT3’s regulation of nuclear gene expression. 
The discovery of a distinct pool of STAT3 that resides in the mitochondria (1, 2) has 
added a new layer to the importance of STAT3 in controlling cellular homeostasis.  
The functional importance of mitochondrial STAT3 (mitoSTAT3) has been 
extensively explored.  MitoSTAT3 has been linked to control of the electron transport 
chain (ETC) and ATP production, mitochondrial encoded RNA regulation, modulation of 
reactive oxygen species generation, Ras transformation, cellular growth, and protection 
from ischemia-reperfusion injuries through regulation of the mitochondrial permeability 
transition pore (MPTP) (3).  Most reports attribute phosphorylation of STAT3 at Ser727  
as being key for its mitochondrial role with the MEK-ERK signaling axis potentially 
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being an important player (4, 5).  However, the signaling pathways that control 
mitoSTAT3 largely still remain to be elucidated. Understanding of such a pathway is 
especially important considering that most studies looking to target STAT3 for 
therapeutic purposes have neglected its mitochondrial role, which could partly explain the 
absence of a clinically usable STAT3 inhibitor(6, 7).  To more effectively study and 
target mitoSTAT3 we sought to examine its regulation at the signaling level. 
We report that mitoSTAT3 was dynamically regulated by various cellular inputs, 
including oxidative stress and cytokines.  Under these conditions mitoSTAT3 abundance 
initially decreased.  This was followed by a re-equilibration of STAT3 into the 
mitochondria that depended upon Ser727 phosphorylation.  During this recovery phase, 
mitoSTAT3 bound to cyclophilin D (CypD), which could play a role in stabilizing the 
mitoSTAT3 pool.  The N-terminus of mitoSTAT3 appeared to be necessary for its 
association with CypD, thereby pointing to an additional site besides Ser727 in STAT3 
that is important for its mitochondrial function.  In this system the N-terminus of STAT3 
also was important for regulating mitochondrial superoxide production following an 
oxidative insult, likely as a consequence of the CypD association.  These results provide 
insight into a signaling pathway that controls the amount of mitoSTAT3, manipulation of 
which may provide new therapeutic modalities to treat diseases associated with 
dysfunctional actions of STAT3.  
 
 
RESULTS 
Rapid Loss of Mitochondrial STAT3 following an Oxidative Stress Insult 
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MitoSTAT3 limits mitochondrial and cellular ROS production(8-12).  STAT3 is 
also post-translationally modified by oxidation that in turn regulates its function (13, 14) 
and ROS may be important for controlling mitoSTAT3 amounts (15). Therefore, we 
examined whether mitoSTAT3 was regulated following an oxidative insult.  When wild-
type MEFs or 4T1 breast cancer cells were treated with H2O2 we observed an initial loss 
of STAT3 from the mitochondria that recovered with time (Figure 1A).  No changes 
were noted in STAT3 amounts in cytosolic fractions from H2O2 treated wild-type MEFs 
or 4T1 cells (Figure 1B), suggesting against nonspecific degradation of mitoSTAT3 as 
being responsible for the loss of the protein. H2O2 also induced phosphorylation of 
STAT3 at both Tyr705 and Ser727 (Supplemental Figures 1A and B), which was 
accompanied by an increase in the nuclear amounts of STAT3 (Supplemental Figure 
1C). The loss of mitoSTAT3 upon treatment with H2O2 was concentration dependent and 
also coincided with activation of mitochondrial extracellular signal-regulated kinase 1 
and 2 (ERK1/2) (Figure 1C).  We noted potent Ser727 phosphorylation of mitoSTAT3 
following H2O2 treatment (Supplemental Figure 1D), but mutation of either Ser727 or 
Tyr705 did not abolish the decrease in mitoSTAT3 amounts (Supplemental Figure 1E).   
The kinetics of this pathway were extremely rapid because treatment with H2O2 
for only 7.5 min. triggered a loss of mitoSTAT3, with recovery starting to occur by 30 
min. (Figure 1D).  The loss of mitoSTAT3 appeared to be specific as mitochondrial 
STAT1 (mitoSTAT1) amounts were unchanged following H2O2 treatment (Figure 1D).  
Probing mitochondrial extracts with a diverse set of STAT3 antibodies targeted to both 
the N- and C-terminus all showed the same loss of mitoSTAT3 upon H2O2 treatment 
making it unlikely that STAT3 was modified such that it is no longer immunoreactive 
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(Supplemental Figure 1F).  Treatment of MDA-231 (ER-/PR-/HER2-) or SK-BR3 (ER-
/PR-/HER2+) human breast cancer cell lines with H2O2 led to a similar loss of 
mitoSTAT3 (Figure 1E) indicating that this pathway is active in receptor negative and 
receptor positive cancer lines alike.  Mitochondria isolated from WI-38 human lung 
fibroblasts that were immediately lysed after treatment with H2O2 also displayed a 
decrease in mitoSTAT3 (Figure 1F).  This result suggested that it was unlikely that 
mitoSTAT3 was going into an insoluble fraction in the mitochondria and pointed to a true 
loss of the protein from this organelle.   It appeared from these experiments and others 
(Supplemental Figure 1G) that the exact timing of the loss and recovery was cell 
dependent.    
 
Loss and Recovery of MitoSTAT3 with Cytokine Administration 
 Because STAT3 is activated by IL-6 family cytokines, which bind to their 
respective receptor and transduce signals through gp130, we investigated whether typical 
STAT3 stimuli produce similar effects on mitoSTAT3.  Treatment of MEFs with 
Oncostatin M (OSM) triggered a loss of mitoSTAT3 within minutes that again recovered 
with time (Figure 2A).  Similar results were obtained when cells were treated with IL-6 
with no apparent decrease in cytosolic STAT3 amounts (Figure 2B). We observed the 
loss and recovery of mitoSTAT3 with cytokine treatment in several mouse and human 
cell lines (Figure 2C, Supplemental Figure 2A).  Longer-term treatment of cells with 
cytokines (16) or growth factors (5, 17, 18) drives an increase in mitochondrial STAT3 
amounts.  This effect was also re-capitulated in MEFs stimulated with OSM for 2H 
suggesting that acute and long-term exposure differentially regulated mitoSTAT3 
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(Supplemental Figure 2B).  Likewise, extended treatment of cells with buthionine 
sulfoximine (BSO), an inhibitor of γ-glutamylcysteine synthetase that with time triggers 
oxidative stress, also led to an increase in mitoSTAT3 (Supplemental Figure 2C).   
The above results implied that signals originating from the plasma membrane 
could be transduced to the mitochondria.  To further explore this possibility we took 
advantage of cell lines containing chimeric receptors expressing the extracellular domain 
of granulocyte colony stimulating factor (GCSF) coupled intracellularly to gp130(19).  
Treatment with GCSF produced the same loss of mitoSTAT3 and subsequent recovery 
(Figure 2D). This mitochondrial signaling pathway was not exclusively driven by gp130 
coupled stimuli because interferon β (IFNβ), a type I interferon that activates STAT3, 
also caused a loss of mitoSTAT3 (Supplemental Figure 2D).  Not all stimuli activate 
this cascade because interferon γ (IFNγ) (Supplemental Figure 2E) and epidermal 
growth factor (EGF) (Supplemental Figure 2F) failed to substantially decrease 
mitoSTAT3. To minimize contamination from the cytosol and other organelles crude 
mitochondria used in these studies were always trypsinized to remove external proteins. 
We further purified mitochondria over a percoll gradient (20) to separate the 
mitochondria from the tightly linked mitochondrial associated membranes (MAM).  
Under these conditions, mitoSTAT3 still decreased with OSM treatment (Figure 2E, P-
mito) confirming a loss of STAT3 selectively from the mitochondrial fraction.  This 
pathway could also be functionally relevant in vivo, but may be difficult to fully explore 
because mice injected with saline alone display a robust decrease in mitoSTAT3 
amounts, likely due to stress pathways induced by injecting the animal (Supplemental 
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Figure 2G).  Together these results show that mitoSTAT3 is dynamically regulated by 
various stressors.      
 
JAK Inhibition and mitoSTAT3 Loss Following Cytokine Treatment 
Since the JAK receptor associated tyrosine kinases drive downstream signaling 
from the IL-6 family cytokines and interferons, we tested whether inhibition of JAK 
kinase activity prevented the loss of mitoSTAT3.  Pre-treatment of MEFs with the pan-
JAK inhibitor Ruxolitinib potently suppressed the loss of mitoSTAT3 induced with either 
OSM (Figure 3A) or IL-6 (Supplemental Figure 3A).  Ruxolitinib did not inhibit H2O2-
induced loss of mitoSTAT3 (Figure 3B), which can likely bypass receptor mediated 
activation and act on other downstream signaling cascades.  These results were mirrored 
in MDA-231 cells pre-incubated with Ruxolitinib and then subjected to either OSM or 
H2O2 treatment (Figure 3C).  Inhibition of STAT3 directly through its SH2 domain with 
the small molecule cryptotanshinone also did not substantially suppress OSM induced 
mitoSTAT3 loss (Supplemental Figure 3B).  This finding is consistent with prior 
reports that demonstrate that the SH2 domain is dispensable for mitoSTAT3’s actions (1, 
2, 11).  Cryptotanshinone also blocks Tyr705 phosphorylation of STAT3 and consistent 
with our results using Y705F STAT3 mutants (Supplemental Figure 1E) it would 
appear that Tyr705 is not involved in the mitochondrial localization of STAT3 after 
stimulation. 
We explored possible downstream mediators that transduce the signal(s) to the 
mitochondria from OSM and H2O2. Notably, H2O2 produced a robust increase in 
mitochondrial ROS production that was not seen with OSM (Figure 3D).  Considering 
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that STAT3 can be regulated by oxidative modifications (21) and various signaling 
pathways can be activated independently of upstream events in the presence of ROS (22), 
we tested whether antioxidants could block the loss of mitoSTAT3 with H2O2 treatment.  
The mitochondrial targeted antioxidant mitoTEMPO (23) did not suppress the H2O2 
induced decrease in mitoSTAT3 (Figure 3E) likely ruling out an oxidative driven 
program. 
Further evaluation of the signaling pathway driving mitoSTAT3 loss revealed that 
Ruxolitinib inhibited ERK activation induced by OSM, but not by H2O2.  STAT3, and in 
particular mitoSTAT3, has been linked to regulation by the MEK-ERK pathway (4), and 
mitoSTAT3 amounts may be controlled by this cascade (5).  The MEK inhibitor 
PD0325901 completely blocked H2O2 mediated activation of ERK, but did not prevent 
mitoSTAT3 loss (10 min. H2O2 treatment) or its initial recovery (30 min. H2O2 treatment) 
(Figure 3F).  This result suggested that the MEK-ERK pathway was dispensable for 
these actions on mitoSTAT3, or alternatively, that there was compensation from another 
signaling cascade.  Treatment with the broad-spectrum kinase inhibitor staurosporine or 
the protein kinase inhibitor H7 dihydrochloride also did not block mitoSTAT3 loss 
(Supplemental Figure 3C).  H7 inhibits kinase A (PKA) and protein kinase C (PKC), 
both of which have been implicated in mitoSTAT3 biology (17, 24).  Other signaling 
cascades converge on STAT3 including p38, PI3K/Akt, JNK, and mTOR (25).  Targeting 
each of these pathways individually did not prevent mitoSTAT3 loss (Supplemental 
Figures 3D-G).  These results imply that multiple signaling events, which likely 
complement each other, may affect mitoSTAT3 making identification of the downstream 
regulation of this pathway challenging.  Though the pharmacological inhibitors used in 
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these studies have other cellular effects, the lack of a response in terms of blockade of the 
mitoSTAT3 loss lends greater support to the complexity of this signaling cascade.   
Although we observe H2O2 and cytokine induced loss of mitoSTAT3 in most cell 
lines, those with low basal amounts of mitoSTAT3, as in the case of the human breast 
cancer cell line MCF-7, often failed to show any further reduction in mitochondrial levels 
of STAT3 (Supplemental Figure 3H). This is consistent with tight regulation of 
mitoSTAT3 levels and cell line and context dependent stimulation of the pathway.  
 
Role of Ser727 Phosphorylation and New Protein Synthesis on mitoSTAT3 Recovery  
 Because we could not definitively link a kinase pathway with the decreases in 
mitoSTAT3 following a stimulus, we investigated the potential contribution of signaling 
driven proteolysis as a mechanism behind mitoSTAT3 regulation.  Consistent with this 
idea, STAT3-/- MEFs expressing a mitochondrially targeted STAT3 and treated with H2O2 
showed the same loss of STAT3 in whole cell extract samples as from mitochondrial 
fractions (Figure 4A).  Though not statistically significant, the trend suggested that the 
mitoSTAT3 loss could be due to protein degradation rather than export of STAT3 from 
the mitochondria and trafficking to another compartment, but we cannot exclude this 
latter possibility. STAT3 is cleaved by proteases such as caspases (26) and calpains (27), 
the latter of which is active in the mitochondria (28).  However, treatment with the 
calpain inhibitor MDL-28170 did not block H2O2 induced mitoSTAT3 loss 
(Supplemental Figure 4A).   
Within the mitochondria, protein degradation is driven by two key serine 
proteases, Lon protease and ClpP Protease, which are essential for mitochondrial protein 
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quality control (29).  We utilized the synthetic triterpenoid CDDO-Me to target Lon 
protease, which inhibits its proteolytic activity in cells (30, 31).  Pre-treatment with 
CDDO-Me also did not block the loss of mitoSTAT3 following an oxidative stress insult 
(Supplemental Figure 4B).  The general proteasome inhibitor MG132, which also 
inhibits Lon protease and attenuates proteasome-mediated outer mitochondrial membrane 
degradation (32), failed to block the decrease in mitoSTAT3 seen with either OSM or 
H2O2 (Figure 4B).  Similarly, primary ClpP-/- MEFs treated with OSM and H2O2 still 
demonstrated loss of mitoSTAT3 (Supplemental Figure 4C). 
Because degradation may play a role in mitoSTAT3 regulation, we tested whether 
or not protein synthesis was needed to drive full recovery of mitoSTAT3 amounts.  
Inhibition of protein synthesis with cycloheximide reduced the return of mitoSTAT3 
following either OSM or H2O2 treatment in MDA-231 cells (Figures 4C and D).  Similar 
results were obtained from H2O2 treated wild-type MEFs incubated with cycloheximide 
(Supplemental Figure 4D).  However, cycloheximide pre-treatment had little effect on 
the cytoplasmic pool of STAT3 (Supplemental Figure 4E) making it more likely that 
cycloheximide may be affecting the chaperone protein that targets STAT3 to the 
mitochondria.  We also cannot exclude the possibility that there is a specific 
mitochondrial pool of STAT3 that is selectively affected by cycloheximide under these 
conditions, or alternatively, that cycloheximide affects some component of the signaling 
pathway through an off-target effect.  Ser727 phosphorylation of STAT3 is important for 
STAT3’s trafficking to the mitochondria and may at least partially regulate its import 
(33).  As such, we speculated that mutation of Ser727 to alanine (S727A) would also 
negatively affect the re-equilibration of mitoSTAT3 following its loss from the 
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mitochondria.  STAT3-/- MEFs expressing S727A STAT3 did not recover to the same 
extent as STAT3-/- MEFs expressing STAT3α after 30’ OSM treatment and amounts of 
mitoSTAT3 only starting to normalize after 1H of treatment in S727A mutant-expressing  
STAT3-/- MEFs (Figures 4E and F).  These results provide insight into the regulation of 
mitoSTAT3 and provide a system through which the signaling pathways controlling 
STAT3 and its mitochondrial localization can be more effectively explored.   
 
Interaction of mitoSTAT3 with Cyclophilin D  
 mitoSTAT3 has been previously linked to regulation of the mitochondrial 
permeability transition pore, potentially through an interaction with Cyclophilin D 
(CypD) (34).  Like other members of the cyclophilin family, CypD is a peptidyl-prolyl 
isomerase that triggers the opening of the permeability transition pore(35). It is also an 
important therapeutic target for ischemia-reperfusion injuries. Prolyl isomerase proteins 
mediate proper folding of target proteins, thus affecting protein stability, localization, and 
activity (36).  Inhibition of CypD with Cyclosporine A (CsA) drives an unfolded protein 
response pointing to a crucial role of CypD as a chaperone protein  (37). Likewise, 
deletion of CypD impairs the function of several mitochondrial proteins (38, 39).  
We noted that STAT3 became competent to bind to CypD after 15’ to 30’ of 
H2O2 treatment (Figure 5A), which corresponds with re-recruitment of STAT3 to the 
mitochondria following mitoSTAT3 loss (Figure 1D).  This result was confirmed in 
purified mitochondrial extracts incubated with recombinant GST-CypD from H2O2-
treated wild-type MEFs (Figure 5B) and 4T1 cells (Figure 5C).  In wild-type MEFs, 
mitoSTAT3 associated with CypD after 30’ of H2O2 treatment, which was maintained 
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until 2-4H after stimulation when mitoSTAT3 amounts had returned to baseline (Figure 
5B, Input bottom panel).  Notably, binding of mitoSTAT3 to GST-CypD was maintained 
out to 4H in 4T1 mitochondrial lysates, likely reflecting the longer time it takes for 
mitoSTAT3 to re-equilibrate following its loss after H2O2 treatment (Figure 1A).  
Incubation of cells with the CypD inhibitor CsA blocked the association of mitoSTAT3 
with CypD making a non-specific interaction between these proteins less likely (Figures 
5B and C).  Similar results were seen in mitochondria from STAT3+/+ or STAT3-/- MEFs 
treated with H2O2 (Supplemental Figure 5A). Incubation with GST alone did not pull 
down any detectable mitoSTAT3, further supporting a specific interaction (Figure 5D).  
Immunoprecipitation of STAT3 from mitochondrial lysates from wild-type MEFs, 4T1 
cells, or MDA231 breast cancer cells treated for 30’ with H2O2 also showed an increased 
association between mitoSTAT3 and CypD compared to untreated controls (Figure 5E 
and Supplemental Figures 5B and C). Binding of mitoSTAT3 to CypD in IL-6-treated 
MDA-231 cells and various OSM-treated cell lines coincided with the recovery phase of 
mitoSTAT3 following stimulation (Figure 5F and Supplemental Figures 5D-F). These 
results suggest that upon STAT3’s re-entry to the mitochondria it binds to CypD, 
potentially as part of its import and proper folding mechanism.  
 
The N-terminus of STAT3 as key for CypD Binding 
      Aside from being critical for the actions of mitoSTAT3, Ser727 in STAT3 may 
also be necessary to facilitate binding to CypD (34). We evaluated whether mutation of 
Ser727 affected STAT3’s interaction with CypD.  GST-CypD pulldown of either 293T 
cells or  STAT3-/- MEFs extracts expressing STAT3 S727A or 4T1 cells expressing 
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STAT3 Y705F/S727A or Y705F/S727D variants revealed that Ser727 did not affect 
STAT3-CypD binding (Supplemental Figures 6A -C). Mutation of Ser727to the 
phospho-mimetic aspartic acid (S727D) seemed to increase basal association of STAT3 
with CypD, potentially reflecting that increased Ser727 phosphorylation of STAT3 may 
promote this protein-protein interaction.  However, STAT3β, a natural occurring splice 
variant that lacks the Ser727 site, bound to CypD following H2O2 treatment 
(Supplemental Figure 6D) suggesting that Ser727 was dispensable for the binding of 
STAT3 to CypD.  
To further evaluate how STAT3 interacts with CypD we used mitoSTAT1, which 
did not bind to CypD (Supplemental Figure 6E).  Using chimeric STAT3:STAT1 
proteins (13, 40) expressed in 293T cells we mapped the region of STAT3 that was 
necessary for the H2O2 induced STAT3-CypD interaction to the N-terminus of STAT3 
(amino acids 1-330 of STAT3) (Figures 6A and B). This result was validated with 
constructs that contain the N-terminus of STAT3 (STAT3/1S) and those with the N-
terminus of STAT1 and the remaining STAT3 C-terminal portion (STAT1/3S) (Figure 
6C).  To further examine the mechanism behind this association, we developed a cell free 
system that used solubilized cell extracts warmed to 30oC.  STAT3 bound to CypD in 
extracts from both 293T cells over-expressing STAT3 and from purified mitochondria 
from MDA-231 cells with endogenous STAT3 (Figures 6D and E).  In both cases, 
binding of STAT3 to CypD was inhibited in the presence of CsA, and STAT3 was not 
detectable in lysates incubated with GST alone (Figures 6D and E).  This cell free 
system provides a useful tool to interrogate the regulation of the interaction of 
mitoSTAT3 and CypD in future studies.  
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Role of a Tyrosine Phosphatase in mitoSTAT3-CypD Interactions  
 Utilizing the cell free system for studying the binding of mitoSTAT3 to CypD we 
sought to further explore the mechanism driving this protein-protein interaction.  Because 
warming of the extracts was sufficient to drive the association of these two proteins, we 
hypothesized that some enzymatic activity was required.  Incubation of extracts with the 
tyrosine phosphatase inhibitor vanadate (Na3VO4) prevented the inducible binding of 
STAT3 to CypD to the same extent as a pan-phosphatase inhibitor (PhosSTOP) (Figure 
6F), which also contains serine/threonine phosphatase inhibitors.  A role for a tyrosine 
phosphatase in this pathway seemed likely because the serine/threonine phosphatase 
inhibitor calycunin A did not affect this interaction (Figure 6F).  These results were 
confirmed in cells pre-treated with vanadate, which blocked the H2O2 induced binding of 
STAT3 to CypD (Figure 7A).  In cell extracts subjected to λ phosphatase treatment 
(Figure 7A), STAT3 bound to CypD to a greater extent, further supporting a role for 
dephosphorylation.  Dialysis of cell extracts to remove small molecules, like ATP, did 
not affect mitoSTAT3’s interaction with CypD pointing to an ATP-independent 
mechanism for this interaction (Figure 7B).  Similarly, incubation of the kinase inhibitor 
Staurosporine in extracts did not prevent the association of mitoSTAT3 with CypD 
(Figures 7A and B).  Together, these results point to a role of a tyrosine phosphatase in 
mediating mitoSTAT3 binding to CypD.   
We examined if STAT3 was the target of the tyrosine phosphatase and needed to 
be modified to interact with CypD. STAT3 added to whole cell extract STAT3-/- MEFs 
that were then incubated at 30oC bound to CypD  (Figure 7C).  However, STAT3 added 
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after extracts were warmed and then placed on ice did not bind to CypD (Figure 7C).  
This result suggested that STAT3 needs to be present during the stimulation and that 
STAT3 itself is likely modified to interact with CypD.  
 
Importance of the STAT3-CypD Association 
The absence of either STAT3 or CypD compromises mitochondrial metabolism 
and overall mitochondrial health (41-43).  Because STAT3 associates with CypD upon its 
return to the mitochondria, we hypothesized that the chaperone function of CypD might 
be important for the stability of mitoSTAT3. MitoSTAT3 amounts were similar in 
CypD+/+ and CypD-/- MEFs following cytokine treatment (Supplemental Figure 6F) 
with the latter at times showing a slight delay in full restoration of mitoSTAT3.  Pre-
treatment with CsA did not affect mitoSTAT3’s signaling regulation, suggesting that 
CypD is not involved in the loss or initial recovery of mitoSTAT3 after H2O2 or cytokine 
treatment (Figure 7D and Supplemental Figure 6G).  As CsA also prevents 
permeability transition, opening of the mitochondrial permeability transition pore 
(MPTP) and its sequelae is unlikely to be an important driving force in the observed loss 
of mitoSTAT3 with external stimuli..  However, these results do not completely address 
whether or not CypD is ultimately required for the stability of mitoSTAT3 as changes in 
the acute setting may only reflect whether or not STAT3 is appropriately targeted and 
imported into the mitochondria.  In some instances, there appeared to be decreased basal 
amounts of mitoSTAT3 in the absence of CypD or after CsA treatment (Figure 7D and 
Supplemental Figures 6F-G).  Based on the sensitivity of the full recovery of 
mitoSTAT3 to cycloheximide (Figure 4C) we examined whether cells lacking CypD 
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relied more heavily on protein synthesis to maintain mitoSTAT3 amounts.  MitoSTAT3 
amounts decreased in CypD-/- MEFs treated with cycloheximide more readily than 
CypD+/+ MEFs (Figure 7E).  These results suggest that CypD may be an important 
binding partner and regulator of mitoSTAT3 stability, most likely through facilitating 
STAT3’s proper folding once it reaches the mitochondria.  
To examine the functional role of the STAT3-CypD association we took 
advantage of the link between mitoSTAT3 and reactive oxygen species production.  
MitoSTAT3 limits mitochondrial and cellular ROS generation (8-12).  We speculated 
that the N-terminus of STAT3 would be essential for contributing to this protective effect 
due to its association with CypD.  STAT3-/- MEFs generated more mitochondrial 
superoxide production than their wild-type counterparts after an oxidative stress (Figure 
7F).  Reconstitution of STAT3-/- MEFs with either wild-type STAT3 or the chimeric 
STAT3/1S construct that contains the N-terminus of STAT3 restored superoxide amounts 
to wild-type amounts (Figure 7F).  These results implicate the N-terminus of STAT3, 
which mediates STAT3’s binding to CypD, as being important in limiting stress induced 
mitochondrial ROS generation.  As we have not evaluated the role of wild-type STAT1 
in this system, we can’t definitely exclude the possibility that the C-terminus of STAT1 is 
not contributing at least in part to the ROS mitigating effect observed with the STAT3/1S 
construct.  However, considering the well-established function of STAT3 in 
mitochondrial ROS regulation (8-12), we anticipate that the majority of the observed 
decrease in superoxide production with re-expression of full-length STAT3 is driven by 
its N-terminus based on the comparable results seen with the 3/1S chimera.        
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DISCUSSION  
mitoSTAT3 affects the ETC, ATP production, mitochondrial ROS generation, 
mtDNA regulation, mitochondrial Ca2+ content, and MPTP susceptibility.  Together this 
regulation drives both normal biological processes and pathological states.  We now add 
to and extend those findings by describing a signaling pathway that acutely regulates 
mitoSTAT3 and drives its association with CypD (Figure 8).   
 MitoSTAT3 is implicated in both cardioprotection in ischemia-reperfusion 
injuries (9, 34, 44-46) and transformation and growth of cancer cells (2, 11, 47-49).  
Understanding how mitoSTAT3 is regulated will be a valuable tool to more effectively 
target the full STAT3 program driving these pathological states.  This is especially 
important because the majority of STAT3 inhibitors designed to date target STAT3’s 
SH2 domain, which likely would not affect mitoSTAT3’s activity as the SH2 domain is 
dispensable for its mitochondrial function (1, 2).  Certain pharmacological treatments 
affect mitoSTAT3 abundance, though their widespread use in manipulating the 
mitochondrial STAT3 pathway remains to be determined(49, 50).  For instance, phospho-
valproic acid limits the translocation of mitoSTAT3 in a pancreatic cancer cell model, 
which leads to increased cancer cell death (49), pointing to the value in targeting 
mitoSTAT3.   
STAT3’s mitochondrial localization can be altered during cell differentiation (15, 
16), with ROS being one mechanism to decrease mitoSTAT3 (15).  Increased 
mitoSTAT3 amounts drive T-cell activation and axonal growth in cells under chronic 
stimulation with cytokines(16) and growth factors (5, 18). Together with the results 
presented here, these reports would suggest that mitoSTAT3 is differentially regulated in 
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the acute compared to chronic setting.  MitoSTAT3 is important in the proliferation of 
embryonic stem cells, where it supports oxidative phosphorylation to couple STAT3’s 
transcriptional effects with maintaining pluripotency (51).  Fine-tuning mitoSTAT3 
amounts then is likely important in controlling mitochondrial adaptation to the real-time 
cellular demands, suggesting that this pathway is a crucial regulatory step in normal 
biological processes as well.   
 Currently, the fate of mitoSTAT3 following stimulation is unknown. Proteolysis 
of mitoSTAT3 is consistent with the kinetics of its loss from the mitochondria. We 
detected proteolytic fragments of STAT3 in the mitochondria but not in cytoplasmic 
extracts suggesting, but not proving, the observed loss of mitoSTAT3 was due to 
proteolysis. Various inhibitors of mitochondrial proteases did not prevent the loss of 
mitoSTAT3.  It is possible that these inhibitors do not enter the mitochondria efficiently, 
or the protease that cleaves mitoSTAT3 is insensitive to the inhibitors used.  Intriguingly, 
both p50 and IκBα is lost from the mitochondria following stimulation with TNFα, with 
IκBα likely being degraded following phosphorylation in part by a calpain-dependent 
mechanism (52). STAT3’s degradation may be linked with its phosphorylation status (53) 
and calpains target and cleave STAT3(27). However, calpain inhibition did not affect on 
treatment-induced mitoSTAT3 loss. Pharmacological blockade of Lon and deletion of 
ClpP proteases, which are serine proteases in the mitochondria, did not attenuate 
mitoSTAT3’s loss.  Other mitochondrial proteases, including inner membrane associated 
mitochondrial AAA proteases, which are emerging as important targets in mitochondrial 
protein quality control and dynamics (29)  may be the primary driver of mitoSTAT3 loss.  
Simultaneous blockade of multiple protease pathways may be necessary to prevent 
! 19!
STAT3 cleavage as inhibition of a single cascade may lead to altered enzymatic activity 
and compensation by another protein.  Consistent with this possibility, inhibition of only 
Lon protease in HeLa cells does not grossly change mitochondrial function or protein 
content due to increased activity from another ATP dependent protease (54).  Another 
explanation for the loss of mitoSTAT3 is that it is removed from mitochondria following 
stimulation through the PINK1-Parkin dependent mitochondrial derived vesicle (MDV) 
pathway (55, 56).  These vesicles remove damaged mitochondrial cargo for transport to 
the lysosome, and are critical to mitochondrial quality control (57).  The mitochondrial 
protein Tom20 is trafficked through these MDVs, and STAT3 is reported to interact with 
Tom20 (34). 
 Our results demonstrate that aside from H2O2, which has broad effects on 
intracellular signaling cascades, cytokines also affected mitoSTAT3 suggesting that 
signals emanating from the plasma membrane were rapidly transduced to the 
mitochondria. We do not know what signaling cascade is responsible for H2O2- and 
cytokine-induced loss of STAT3 from the mitochondria.  Although various kinases, 
including Akt, ERK, and JNK, have been reported to reside in the mitochondria where 
they regulate mitochondrial dynamics through phosphorylation events (58-60)(61), 
inhibition of these mitochondrial-localized signaling proteins in isolation did not affect 
stimulus dependent decreases in mitoSTAT3.  
The dependence of the recovery of mitoSTAT3 after stimulation on Ser727 
phosphorylation agrees with a prior report that demonstrated the Ser727 site is important 
for its mitochondrial import (33).  The absence of an effect on basal mitoSTAT3 amounts 
when Ser727 is mutated to an alanine (S727A) suggests though, that there are likely other 
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means of bypassing this import requirement that are compromised under stress 
conditions.  Like other proteins that are imported into mitochondria, the mitochondrial 
import of STAT3 requires an intact mitochondrial membrane potential (62). STAT3 is 
ultimately being targeted to the inner mitochondrial membrane or matrix (33, 34).  Under 
stress conditions, a reduction in mitochondrial membrane potential disables the 
mitochondrial import machinery, which affects the import efficiency and mitochondrial 
abundance of various proteins (63, 64).  However, continuous import of STAT3 to 
maintain its mitochondrial abundance is unlikely because mitoSTAT3 was remarkably 
stable in wild-type cells hours after cycloheximide treatment (Figure 7E). Although the 
MEK-ERK pathway phosphorylates STAT3 at Ser727 and has been linked to regulating 
mitoSTAT3(4, 5), MEK and ERK inhibition did not affect mitoSTAT3 abundance.  This 
is not surprising because various other kinases can phosphorylate STAT3 at this residue, 
and there is likely a large degree of crosstalk between multiple signaling pathways.  The 
full recovery of mitoSTAT3 was blunted when protein synthesis was inhibited, despite 
the large cytoplasmic pool of STAT3 that was still present under these conditions.  These 
results suggest that either the chaperone protein that is responsible for the translocation of 
STAT3 to mitochondria has a short half-life or there is a limited fraction of STAT3 that 
can go to the mitochondria.  The latter idea is interesting and could be analogous to p53, 
of which there is a distinct mitochondrial isoform (65).  Other isoforms of STAT3 have 
been reported but to date there is no information on whether or not they, or others, are 
mitochondrially localized (66).   
Based on the above results (Figure 4) we anticipate that mitoSTAT3’s loss is 
likely due to proteolysis.  However, a fraction of mitoSTAT3 could traffic to another 
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cellular compartment.  Signaling to the nucleus would be an attractive target, considering 
STAT3’s role as a nuclear transcription factor.  Under the conditions which induced loss 
of mitoSTAT3, STAT3 was potently recruited to the nucleus making it at least plausible 
that the mitochondrial pool of STAT3 might contribute to the nuclear actions of STAT3.  
However, this possibility is difficult to assess because of high cytosolic abundance of 
STAT3. Other mitochondrial proteins, including the pyruvate dehydrogenase complex 
and SSBP1, can translocate from the mitochondria to the nucleus to regulate transcription 
under stress conditions (67, 68).  This mitochondrial retrograde signaling event occurs in 
Caenorhabditis elegans, where the protein ATFS-1 links coordinate mitochondrial and 
nuclear programs (63, 69, 70).  Intriguingly, ATFS-1 is also proteolyzed in the 
mitochondria and accumulates in the nucleus under stress conditions. A similar pathway 
has not been detected in mammalian cells, but it is thought that signaling molecules such 
as ROS or Ca2+ released from mitochondria might activate pathways (such as JNK) to 
drive mito-nuclear crosstalk (71).  STAT3 not only modulates mitochondrial ROS 
production (9, 11, 12, 15, 45), but it also directly regulates mitochondrial calcium 
content(16).  It is tempting to speculate that mitoSTAT3, as well as other transcription 
factors that localize to the mitochondria such as NFκΒ, might be part of this 
communication network, especially when one considers the dynamic regulation we have 
observed in mitoSTAT3.  Whether this is through direct trafficking to the nucleus, or 
indirectly through regulation of intracellular ROS and Ca2+ content remains to be 
determined. 
CypD plays a role in retrograde signaling through its effects on STAT3 activation 
(72).  It is interesting then that mitoSTAT3 binds to CypD in an inducible manner.  The 
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interaction of STAT3 and CypD coincides with mitoSTAT3’s return to the mitochondria. 
Re-entry of proteins into the mitochondria requires their proper folding after 
mitochondrial import, and the chaperone function of CypD may play a critical role in this 
process.  Indeed, the decreased mitoSTAT3 amounts in cells lacking CypD following 
cycloheximide treatment suggest that the stability of the mitoSTAT3 pool at least partly 
depends on CypD.  mitoSTAT3 that is serine phosphorylated associates with CypD in 
cardiomyocyte mitochondria, where it plays a role in regulation of MPTP sensitivity (34).  
Surprisingly, we observed that Ser727 in STAT3, which has been implicated in its 
mitochondrial action, was not required for the binding of mitoSTAT3 to CypD.  Rather, 
the N-terminus of STAT3 mediates the association suggesting that other domains in 
mitoSTAT3 are relevant for its non-canonical mitochondrial role.  Interestingly, selective 
targeting of the N-terminus of STAT3 with peptide-based inhibitors affects mitochondrial 
membrane potential and lead to cancer cell death(73).  
The action of a tyrosine phosphatase on STAT3 was necessary for its interaction 
with CypD.  This is interesting as binding of STAT3 to CypD can be potently induced 
with H2O2, a stimulus that normally inhibits tyrosine phosphatases through oxidation of 
key cysteines in their catalytic pocket (74).  A major regulator of STAT3 signaling is the 
Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) (75).  
Coincidentally, SHP2 is also paradoxically activated by oxidative stress (76), and it can 
localize to the mitochondria where it regulates mitoSTAT3 (77).  Future work will clarify 
the identity and role of this phosphatase in this signaling cascade. 
Consistent with prior reports (8-12), we have demonstrated a role for STAT3 in 
the modulation of cellular ROS.  We extend that work by demonstrating that the N-
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terminus of STAT3 may be key for limiting mitochondrial ROS production after stress 
insult.  Because the N-terminus of STAT3 was also the critical region for binding to 
CypD, we anticipate that the STAT3-CypD association is important for regulating ROS 
generation at the mitochondrial level.  This could be through stabilization of the 
mitoSTAT3 pool allowing STAT3 to more effectively alter ETC activity under stress 
conditions as previously proposed (45).  Increased amounts of mitoSTAT3 could also 
serve as a greater redox reserve effectively scavenging mitochondrial reactive oxygen 
species as they are generated (14).  It is also conceivable that the association of 
mitoSTAT3 with CypD directly controls the opening of the mitochondrial permeability 
transition pore (34) that is closely linked to cellular redox status.  Work is ongoing to 
better understand how this protein-protein interaction affects this functional endpoint.  
Tight regulation of cellular redox state is paramount during cellular transformation and 
progression of cancer. Interestingly, CypD is necessary for Ras transformation and 
tumorigenesis(78). Because mitoSTAT3 is necessary for Ras transformation (2) it is 
tempting to speculate that CypD’s requirement in this process is through its binding and 
stabilization of the mitoSTAT3 pool. Further characterization of this cascade and how 
mitoSTAT3 is controlled is necessary to provide insight into how to effectively target the 
mitochondrial pool of STAT3 for the purposes of promoting health and combating 
disease. 
MATERIALS AND METHODS 
Cell Culture 
The following cell lines were used in this study: Wild-type Mouse Embryonic Fibroblasts 
(MEFs), STAT3-/- MEFs, CypD-/- MEFs, ClpP+/+ MEFs, ClpP-/- MEFs, 4T1 murine breast 
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adenocarcinoma cells, MDA-MB-231 triple negative human breast cancer cells, WI-38 
human lung fibroblasts, SKBR3 HER2+ human breast cancer cells, BT474 HER2+ human 
breast cancer cells, MDA-MB-453 HER2+ human breast cancer cells, 293T human 
embryonic kidney cells, HeLa human cervical cancer cells, and rat hepatoma cell lines 
expressing the GCSF-gp130 chimeric receptor.  The human breast cancer cell lines were 
kindly provided by Drs. Gordon Ginder, Charles Clevenger, and Frank Fang, Virginia 
Commonwealth University. WI-38 human lung fibroblasts were provided by Dr. Swati 
Deb, Virginia Commonwealth University.  HeLa cells were provided by Dr. Thurl Harris, 
University of Virginia.  CypD-/- MEFs were kindly provided by Dr. Ute Moll, Stony 
Brook University.  ClpP+/+ and ClpP-/- MEFs were kindly provided by Dr. Georg 
Auburger, Goethe - Universität.  Rat hepatoma cell lines were provided by Dr. Heinz 
Baumann, Roswell Park Cancer Institute.  Cells were routinely grown in appropriate 
growth culture (DMEM, DMEM F-12, or RPMI) media supplemented with 10% heat 
inactivated Fetal Bovine Serum (Serum Source International, Charlotte, NC) and 50U/mL 
Penicillin and 50ug/mL Streptomycin (Life Technologies). Prior to experimental use cell 
lines were determined to be free of mycoplasma contamination.  
Reagents 
The following chemicals and inhibitors were used: Ruxolitinib (JAK inhibitor, 5µM, 
Selleck Chemicals), PD0325901 (MEK inhibitor, 10µM, Selleck Chemicals), LY294002 
(PI3K inhibitor, 25µM, Cell Signaling), SB203580 (p38 MAPK inhibitor, 10µM, 
Calbiochem), SP600125 (JNK inhibitor, 50µM, Cell Signaling), Torin 1(mTOR inhibitor, 
10µM, Tocris Biosciences), Cyclosporine A (Cyclophilin D inhibitor, 5µM or 10µg/mL, 
Sigma), Cycloheximide (Protein synthesis inhibitor, 50µg/mL, MP Biomedicals), 
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Staurosporine (Tyrosine Kinase inhibitor, 100nM, Sigma), H7 Dihydrochloride (Protein 
Kinase A/C/G inhibitor, 20µM, Sigma), Cryptotanshinone (STAT3 inhibitor, 10µM, 
Selleck Chemicals), mito-TEMPO (mitochondrial anti-oxidant, 100µM, Sigma), MG132 
(Proteasome Inhibitor, 25µM, Tocris Biosciences), MDL-28170 (Calpain Inhibitor, 
10µM, kind gift from Dr. Ed Lesnefsky, Virginia Commonwealth University, Richmond, 
VA) CDDO-Me (Lon Protease Inhibitor, 50µM, Sigma), recombinant murine IL-6 
(50ng/mL, Peprotech), recombinant human IL-6 (50ng/mL, Peprotech), soluble human 
IL-6Rα (50ng/mL, Peprotech), human OSM with carrier (12.5ng/mL, Cell Signaling), 
mouse OSM with carrier (12.5ng/mL, Cell Signaling), Hydrogen Peroxide 30% Solution 
(1mM unless otherwise indicated, Sigma), cOmplete protease inhibitor cocktail (per 
manufacturer’s instructions, Roche), phosSTOP phosphatase inhibitor cocktail (per 
manufacturer’s instructions, Roche).  All other chemicals used for buffer formulations 
were purchased from Sigma-Aldrich or Fisher Scientific unless otherwise indicated. 
Treatments 
All stimulations were carried out in cells cultured in full serum media (10%) so as to 
avoid any effect of serum starvation on mitoSTAT3 amounts.  Aside from protease 
inhibitor studies (4H pre-treatment), all other inhibitors were pre-incubated on cells for 
no more than 1H prior to H2O2 or cytokine treatment. Vehicle or DMSO treatments were 
used when appropriate as controls.        
Plasmids  
pGEX-CypD was a kind gift from Dr. Ute Moll, Stony Brook University(79).  pRC-CMV 
STAT3, pRC-CMV STAT1, pRC-CMV STAT3/1H, pRC-CMV STAT3/1S, pRC-CMV 
STAT1/3H, and pRC-CMV STAT1/3S have been described previously (13). MSCV-
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IRES-GFP expression vectors containing STAT3α, STAT3β, STAT3 Y705F, STAT3 
S727A, STAT3 S727D, MLS-STAT3 and the Phoenix helper construct have been 
previously described (1)  
Transfections 
Transfections were carried out with the use of FuGENE (Promega).  Briefly, plasmid 
DNA (1-3µg) was combined with FuGENE reagent at a 1:3 ratio (µg:mL) and incubated 
in OPTI-MEM media for 5 minutes prior to adding to cells.  For shRNA viral 
transductions, 293T cells were transfected via FuGENE with the indicated shRNA vector 
(1.5µg), pCMV-VSV-G envelope protein vector (1µg), and pCMV-dR8.2 dvpr 
packaging plasmid vector (1.5µg).  Viral supernatants were collected after 48H, spun 
down, and filtered through a 0.45µm filter prior to adding to cells in the presence of 
10µg/mL Polybrene (Millipore).  MSCV retroviruses were similarly packaged in 293T 
cells following transfection with the appropriate MSCV viral vector (4µg) and the 
phoenix helper construct (1µg).  Cell transductions were carried out for 24H in the 
presence of virus and after 48H puromycin selection (2µg/mL, shRNA experiments) or 
GFP FACS sorting was performed to generate a pure, stable pool of cells expressing the 
indicated viral vector.          
Recombinant Proteins 
pGEX-CypD and pGEX vectors were transformed into BL-21(DE3) competent bacteria.  
Bacterial clones containing the plasmid of interest were grown up overnight in 25mL of 
LB media and the following morning was diluted 1:15 into a 500mL culture.  Bacteria 
were grown up until OD600 reached 0.6 at which point protein expression was induced 
with 1mM IPTG for 6H.  The bacteria were pelleted and lysed in bacterial lysis buffer 
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followed by sonication.  The bacterial cell extract was then incubated with glutathione 
sepharose 4B beads (GE Healthcare, #17-0756-01) for 1H at 4oC.  Bead bound GST 
proteins were pelleted and washed 3X in bacterial lysis buffer prior to storage at -80oC.  
A portion of the purified proteins were resolved by SDS-PAGE and gels were fixed and 
Coomassie stained for quantification of GST recombinant proteins as compared to a BSA 
standard curve. Recombinant Flag-STAT3 protein was a kind gift from Claudia Mertens, 
Rockefeller University, Darnell Lab(80). 
SDS-PAGE and Immunoblotting 
Cell samples were lysed in 20mM HEPES, pH 7.4, 300mM NaCl, 10mM KCl, 1mM 
MgCl2, 20% glycerol, and 1% Triton X-100. Equal protein was loaded on Tris-glycine 
gels and subjected to SDS-PAGE electrophoresis.  Gels were transferred to PVDF 
membranes (Millipore, IPVH00010) using a semi-dry transfer apparatus.  The following 
antibodies were used overnight at 4oC with shaking following blocking for 1H in 5% 
milk or 5% BSA in 1X TBS + 0.1% Tween-20: STAT3 (Cell Signaling #9139, mouse 
monoclonal, clone 124H6), STAT3 (N-terminal, BD Biosciences, mouse monoclonal), 
STAT3 (Cell Signaling, rabbit polyclonal), pTyr705  STAT3 (Cell Signaling , mouse 
monoclonal), pSer727 STAT3 (Cell Signaling, rabbit polyclonal), Complex V Subunit I 
(Abcam, mouse monoclonal), STAT1 (BD Biosciences, mouse monoclonal), pTyr701 
STAT1 (Cell Signaling, rabbit polyclonal), CypD (PPIF, Abcam, mouse monoclonal), 
Calreticulin (Cell Signaling, rabbit monoclonal), Histone H3 (Cell Signaling, mouse 
monoclonal), Lamin A/C (Cell Signaling, mouse monoclonal) ATP5O (Abcam, mouse 
monoclonal), GRIM19 (Abcam, mouse monoclonal), pAkt (Cell Signaling, rabbit 
polyclonal), pc-Jun (Cell Signaling, rabbit polyclonal), NDUFA9 (Abcam #ab14713, 
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mouse monoclonal), pERK1/2 (Cell Signaling #9101, rabbit polyclonal), Tubulin (Sigma 
#T8203, mouse monoclonal, α-Tubulin), Actin (Cell Signaling, mouse monoclonal)  
Secondary antibodies were used at a concentration of 1:5000 for 1H at room temperature 
in 5% milk in 1X TBS + 0.1% Tween-20. 
After washing, blots were incubated with Amersham ECL (GE Healthcare, RPN2106) or 
ECL2 Western Blotting (Thermo-Scientific, 80196) chemiluminescent detection reagents 
and developed.  Where indicated densitometry quantification was performed using 
ImageJ Software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://imagej.nih.gov/ij/, 1997-2015). 
Mitochondria Isolation 
Pure mitochondria and mitochondria-associated membrane (MAM) fractions were 
isolated as previously described(81). For crude mitochondria adherent cells were treated 
and then washed with ice cold 1X PBS, trypsinized, and collected with ice cold full 
serum media.  Cells were spun down for 5min. at 1000RPM and the pellets were washed 
1x with 3mL’s of ice cold 1X PBS.  Cells were spun down again for 5min. at 1000RPM 
and the supernatant was aspirated.  The cell pellets were resuspended in an appropriate 
volume (1-2mL’s) of sucrose buffer (10mM HEPES, pH 7.4, 250mM sucrose, 1mM 
EDTA, protease and phosphatase inhibitors) and incubated on ice for 10min.  Cells were 
then added to a douncer (all steps on ice) and cells were homogenized with manual 
strokes until roughly 90% of the cells were broken (verified with Trypan blue during 
douncing).  Cells were collected and spun down for 5min. at 800g at 4oC to pellet 
unbroken cells and nuclei.  The supernatant was collected and spun down for 10min. at 
8800g at 4oC to pellet crude mitochondria.  The supernatant was again collected and 
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transferred to a new tube labeled cytosolic fraction, which was spun down for 10min. at 
10000g at 4oC to remove any contaminants from the cytosolic sample.  After this spin the 
cytosolic supernatant (700µL) was transferred to a new tube and frozen at -80oC until 
further analysis.  The crude mitochondrial pellet from above was resuspended in 490µL 
sucrose buffer and 10µL of a 5mg/mL stock solution of trypsin was added to each tube 
(for a final concentration of 100µg/mL).  Samples were then rotated for 10min. at 4oC 
after which 500µL of a 5% BSA solution was added to each tube to inactivate the trypsin.  
Samples were again rotated for 1min. at 4oC and then spun down at 10000g for 10min. at 
4oC.  The supernatant was aspirated off (including the trypsin digested material 
surrounding the mitochondrial pellet) and the mitochondrial pellets were washed in 
500µL of sucrose buffer 2X (spins done at 10000g for 10min. at 4oC).  After the final 
wash the mitochondrial pellets were resuspended in an appropriate volume of sucrose 
buffer and stored at -80oC until further analysis.  For protein analysis mitochondrial 
supernatants were lysed in an equal volume of sucrose buffer plus 1XPBS with 2% Triton 
X-100 plus protease and phosphatase inhibitors.  
Pulldown Assays 
Pulldown assays were performed as previously described(79).  Briefly, recombinant 
bead-bound GST-CypD or GST alone was blocked in H-buffer (20mM HEPES pH 7.7, 
1mg/mL BSA, 75mM KCl, 0.1mM EDTA, 2.5mM MgCl2, 0.05% NP-40, 1mM DTT).  
250µg of mitochondrial or whole cell extracts (lysed as described above) were incubated 
with 20µg of bead bound GST-CypD or GST alone and incubated overnight at 4oC.  
Beads were pelleted and washed in H-buffer and bound proteins were analyzed by 
immunoblotting. 
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Immunoprecipitation 
Immunoprecipitation was carried out as previously described (82). Mitochondrial or 
whole cell extracts were incubated overnight at 4°C with an antibody against STAT3 
(SantaCruz, sc-482, C-20, 1:100 dilution) plus agarose beads (Protein G Sepharose Fast 
Flow, GE Healthcare, 17-0618-01) or control IgG plus agarose beads in IP buffer (pH 
7.4, 150 mM NaCl, 50mM Tris-HCl, 1% Triton, 1 mM EDTA with protease and 
phosphatase inhibitor cocktails (Roche, Indianapolis, IN). Immunoprecipitates were 
washed three times with wash buffer (150 mM NaCl, 50mM Tris-HCl, 1% Triton, 
protease and phosphatase inhibitor cocktails), and separated by SDS-PAGE with blotting 
against the indicated antibodies. 
Cell Free System for studying mitoSTAT3-CypD Interactions 
Mitochondria or whole cell extracts were prepared as described, but importantly in the 
absence of protease or phosphatase inhibitors.  Lysates were incubated on ice or at 30oC 
for 30 minutes in 1X NEBuffer for Protein Metallophosphatases (50mM HEPES, 10mM 
NaCl, 1mM MnCl2, 2mM DTT, 0.01% Brij 35, pH 7.5).  Following incubation, extracts 
(100µg) were subjected to GST-CypD pulldown as described.  When applicable cell 
lysates were dialyzed for 3H using a 10,000MWCO dialyzer cassette according to the 
manufacturer’s protocol (Slide-A-Lyzer, Thermo Fisher Scientific).    
Animals 
Animals were treated in compliance with the Guide for the Care and Use of Laboratory 
Animals under the protocols approved by Virginia Commonwealth University 
Institutional Animal Care and Use Committee. 
Liver Mitochondrial Assays 
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8-12 week old male CD-1 mice (Charles River Laboratories) were tail vein injected with 
500µg/kg recombinant murine IL-6 (Peprotech) and sacrificed at the indicated times.  
Livers were harvested from mice and washed with ice cold PBS. The livers were minced 
and homogenized in 10mL MSM (220mM Mannitol, 70mM Sucrose, 5mM MOPS) on 
ice.  A homogenate fraction was collected for each sample and solubilized as described 
abover. Homogenized tissues were then centrifuged at 500xg for 10 minutes at 4°C to 
remove cell debris. The supernatants were centrifuged at 3700xg for 10 minutes at 4°C to 
pellet mitochondria. Mitochondria were re-suspended in 5mL of ice cold MSM-EDTA 
(MSM Buffer plus 2mM EDTA) and spun at 3700xg for 10 minutes at 4°C. Supernatants 
were discarded and the mitochondria were re-suspended in 2.5mL of MSM-EDTA buffer 
and spun down at 3700xg for 10 minutes at 4°C (83).  Mitochondria in MSM-EDTA 
buffer were lysed via the addition of an equal volume of 2% Triton X-100 in 1X PBS 
with protease and phosphatase inhibitor cocktails and analyzed via immunoblotting.   
Statistical Analysis  
Results are presented as the mean ± SEM.The statistical analysis was carried out as 
follows. For Figures 1A and Supplementary Figure 1D, differences between the Control 
and the groups under comparison were assessed using a two-sided 2-sample t-test at 5% 
level of significance. For Figure 1D, differences between mitoSTAT3 and mitoSTAT1 at 
various times of H2O2 treatment were assessed using two-sided 2-sample t-test at 5% 
level of significance. For all others, the differences between groups were initially 
assessed using a one-way ANOVA, followed by false discovery rate (FDR) (84) adjusted 
multiple (pairwise) comparisons at a 5% threshold. If P values were < 0.05, we 
considered the group difference to be significant. N values are indicated in the figure 
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legends for each panel and always represent independent experiments.  Representative 
blots are shown.   
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FIGURE LEGENDS 
Figure 1: Oxidative Stress Triggers a Loss of Mitochondrial STAT3. Wild-type (WT) 
MEFs or 4T1 cells were treated with 1mM H2O2 for the indicated times and 
mitochondrial (mito) (A) or cytosolic (cyto) (B) extracts were probed for STAT3.  
Quantification of mitoSTAT3 as compared to a loading control is depicted in (A).  
*p<0.05 (compared to control), ; #p<0.05 (compared to control). Blots are representative 
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of 3 independent experiments. (C) WT MEFs treated with the indicated concentrations of 
H2O2 and extracts probed for mitoSTAT3 (top panel) and phosphorylated (p) Tyr705 and 
total STAT3 in the cytosol (bottom panel) (Tubulin: cytosolic loading control; CypD: 
mitochondrial loading control). Blots are representative of 2 independent experiments.  
(D) Isolated mitochondria from WT MEFs treated for the indicated times with H2O2 were 
immunoblotted for mitoSTAT3 or mitoSTAT1 and quantified. *p<0.01, **p<0.04, 
#p<0.005. Blots are representative of 3 independent experiments. (E) MDA-231 and SK-
BR3 human breast cancer cells were treated for the indicated times with H2O2 and 
immunoblotted for STAT3 and GRIM19 (mitochondrial loading control). Blots are 
representative of 2 independent experiments. (F) WI-38 human lung fibroblasts were 
treated with H2O2 and purified mitochondria were immediately lysed in sample buffer.  
Blots were probed for mitoSTAT3, pERK1/2, and NDUFA9 (mitochondrial loading 
control). Blots are representative of 2 independent experiments.   
 
Figure 2: Cytokine Treatment of Cells Induces mitoSTAT3 Loss and Recovery.   
(A and B) WT MEFs were treated with either OSM (A) and IL-6 (B) for the indicated 
times and mitochondrial extracts were immunoblotted for STAT3, pERK, tERK, and a 
loading control (NDUFA9 and/or CypD) (top panels).  Cytosolic extracts probed for 
pTyr705 STAT3 are shown to confirm cell activation (lower panels). Blots are 
representative of 2 independent experiments.  (C) Mitochondria from 4T1 cells treated 
with OSM (upper panel) or MDA-231 cells treated with IL-6 (bottom panel) were probed 
for STAT3 and loading control (GRIM19 or CypD). Blots are representative of 2 
independent experiments.  (D) Rat hepatoma cell lines expressing the chimeric GCSF-
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gp130 receptor were stimulated with recombinant human GCSF and immunoblotted for 
STAT3 in the mitochondrial fraction or pTyr705 STAT3 in the cytosolic fraction. Blots 
are representative of 2 independent experiments. (E) Purified mitochondria (P-Mito) 
from control or OSM stimulated WT MEFs were fractionated into cytosolic (cyto), ER 
(endoplasmic reticulum), crude mitochondria (C-mito), pure mitochondria (P-mito), and a 
mitochondrial associated membrane fraction (MAM) and blotted against a total 
homogenate fraction (Homog.).  The abundance of Calreticulin (ER and MAM marker), 
Tubulin (cytosolic marker), NDUFA9 (mitochondrial marker), Histone H3 (nuclear 
marker), and STAT3 is shown. Blots are representative of 2 independent experiments 
.      
Figure 3: Inhibition of JAKs Prevents mitoSTAT3 Loss Upon Cytokine Treatment. 
(A and B) MEFs were incubated with or without the JAK inhibitor ruxolitinib for 1H 
prior to the addition of OSM (A) or H2O2 (B), and mitochondrial and cytosolic extracts 
were immunoblotted for STAT3 or pTyr705 STAT3 respectively. Blots are representative 
of 3 independent experiments. Densitometric quantification of mitochondrial results from 
(A) is depicted. * p<0.01, # p<0.001, ns=not significant. (C) Mitochondria were isolated 
from MDA231 breast cancer cells treated with ruxolitinib for 1H prior to the addition of 
OSM or H2O2 for the indicated times and immunoblotted for STAT3 and NDUFA9 
(loading control). Blots are representative of 2 independent experiments. (D) 
Mitochondrial superoxide production was assayed by flow cytometry analysis using the 
MitoSOX dye in WT MEFs treated for 30’ with either OSM or H2O2.  *p=0.0002, 
**p=0.0002. N=3 independent experiments.  (E) WT MEFs were pre-treated for 1H with 
the mitochondrial restricted anti-oxidant mitoTEMPO and then stimulated for 30’ with 
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H2O2 with mitochondrial extracts blotted for STAT3, pERK1/2, or NDUFA9 (loading 
control). Blots are representative of two independent experiments.  (F) WT MEFs were 
pre-treated with the MEK inhibitor PD0325901 for 1H followed by H2O2 treatment for 
the indicated times and isolated mitochondria were subjected to SDS-PAGE and 
immunoblotted for STAT3, pERK1/2, tERK1/2, and NDUFA9 (loading control).  Blots 
are representative of 2 independent experiments.    
 
Figure 4: Recovery of mitoSTAT3 is Dependent on New Protein Synthesis and S727 
Phosphorylation of STAT3. A) STAT3-/- MEFs were engineered to stably express 
mitochondrial targeted STAT3 (MLS-STAT3) and subjected to H2O2 treatment.  Whole 
cell extract (WCE) and mitochondria were western blotted for STAT3 or the respective 
loading control. Blots are representative of 3 independent experiments and densitometric 
quantification is shown.  (B) Mitochondria from MDA-231 cells were pre-treated for 4H 
with vehicle or MG132 and treated with OSM or H2O2 and extracts probed for STAT3.  
Cytosolic extracts from vehicle or MG132 treated cells were probed for Ubiquitin (Ub) 
(right panel). Blots are representative of 2 independent experiments. (C and D) 
Mitochondrial extracts from MDA-231 cells treated with or without cycloheximide and 
stimulated with OSM or H2O2 were subjected to western blotting (C). Results from OSM 
experiments were quantified in (D) by densitometry analysis.  *p=0.009; #p=0.023, 
ns=not significant. N=3 independent experiments. (E and F) STAT3-/- MEFs expressing 
WT STAT3 (STAT3α) or the nonphosphorylatable mutant (STAT3 S727A) were treated 
for the indicated times with OSM and mitochondrial lysates were immunoblotted for 
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STAT3 (E).  Quantification of these results are presented in (F). *p<0.005; #p≤0.0002, 
**p<0.002, ***p<0.02, ns=not significant. N=3 independent experiments.   
Figure 5: mitoSTAT3 Interacts with CypD. (A) Lysates from WT MEF whole cell 
extracts treated with H2O2 were subjected to pulldown with bead-bound GST-CypD 
(coomassie stain) and probed for STAT3 (Input, lower panels). Blots are representative of 
2 independent experiments. (B and C) WT MEFs (B) and 4T1 cells (C) were incubated 
with H2O2 for various times prior to isolation of mitochondria. Extracts were incubated 
with GST-CypD in the presence (lane 6) or absence of CsA and STAT3 was assayed by 
immunoblots (upper panels). Lower panels show the input (10% of that used for the pull 
downs). Blots are representative of 2 independent experiments. (D) Mitochondria from 
4T1 cells either untreated or treated with H2O2 were subjected to GST-CypD or GST 
pull-down with immunoblotting for STAT3 or GST. Input is shown in the lower panels. 
Blots are representative of 2 independent experiments. (E) MitoSTAT3 
immunoprecipitations (IPs) from MEFs and 4T1 cells treated 30 min with H2O2. 
Immunoblots were probed for STAT3 (lower panels) or CypD (upper panels). Input (10% 
of that used for immunoprecipitation) is shown. Blots are representative of 2 independent 
experiments. (F) GST-CypD pulldown of mitochondrial extracts from MDA-231 cells 
treated with IL-6 and the soluble IL-6Rα with input shown below.  Blots were probed for 
STAT3. ATP5O is shown as a loading control for the pulldown and input samples.     
 
Figure 6: Binding of mitoSTAT3 to CypD is Mediated through STAT3’s N-terminus 
and can be re-capitulated in a cell free system. 
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(A) 293T cells expressing various chimeric versions of Flag tagged STAT3/STAT1 were 
treated with H2O2 and whole cell extracts were incubated with GST-CypD and probed for 
Flag (upper panel). Lower panels show the input (10% of that used for the pull downs) 
with coomassie stain of the GST-CypD input. Blots are representative of 3 independent 
experiments. (B) Diagram of the chimeric constructs used in (A) indicating the critical 
region (green bar) in STAT3 that mediates its binding to CypD (13).  (C) 293T cells 
expressing STAT3/1S or STAT1/3S were treated with H2O2, subjected to GST-CypD 
pulldown and probed for Flag (pulldown: top panel, input: bottom panel). Blots are 
representative of 2 independent experiments.  (D) 293T cell lysates expressing 
STAT3/1H were warmed to 30 degrees and incubated with either GST-CypD or GST 
alone and immunoblotted for Flag.  CsA was incubated with warmed lysates to also show 
specificity of the interaction (lane 5).  Bottom panel depicts Coomassie stain for GST-
CypD and GST. Blots are representative of 2 independent experiments.  (E) 
Mitochondrial lysates from MDA-231 cells tested in the cell free system were incubated 
at 30 degrees and a GST-CypD pulldown was performed in the presence or absence of 
CsA with immunoblotting for STAT3 and ATP5O. Blots are representative of 2 
independent experiments.  (F) Extracts from 293T cells expressing the chimeric protein 
STAT3/1H were warmed to 30o in the established cell free system in the presence of 
vanadate (Na3VO4), calycunin A, or the pan-phosphatase inhibitor cocktail PhosSTOP 
(Roche).  Lysates (left panel, input) were subjected to GST-CypD pulldown (right panel) 
and probed for Flag (STAT3).  Coomassie stain of GST-CypD is shown (right panel, 
bottom) to confirm equal loading of recombinant CypD. Blots are representative of 2 
independent experiments.  
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Figure 7: A Tyrosine Phosphatase Mediated Event Drives mitoSTAT3-CypD 
Interactions. (A) 293T cells expressing STAT3/1S were pre-treated with either Vanadate 
(Na3VO4) or Staurosporine followed by treatment with H2O2 for 1H.  Untreated lysates 
were also subjected to λ phosphatase (phos) treatment or mock treatment.  GST-CypD 
pulldown samples (top) and the corresponding input (bottom panels) were probed for 
Flag (STAT3) with the input also immunoblotted for Tubulin (loading control) and 
pERK1/2.  Coomassie stain of GST-CypD is shown (bottom panel) to confirm equal 
loading of recombinant CypD. Blots are representative of 2 independent experiments. (B) 
Extracts from 293T cells expressing STAT3/1H were dialyzed prior to mock treatment 
(30oC) with or without the addition of ATP (20mM).  Staurosporine was included during 
the mock treatment period for lysates in lanes 4 and 5.  Binding of STAT3 and CypD was 
assessed by GST-CypD pulldown. Blots are representative of 3 independent experiments. 
(C) Whole cell extracts from STAT3-/- MEFs were incubated with recombinant STAT3 on 
ice or either during (+pre) or after (+post) warming of the extract at 30o for 30 min.  Input 
(bottom panel) and GST-CypD pulldowns were probed for STAT3. Blots are 
representative of 3 independent experiments. (D) MDA-231 human cancer cells were pre-
treated with CsA and then treated with OSM and mitochondrial lysates were probed for 
STAT3. Blots are representative of 2 independent experiments.  (E) CypD+/+ MEFs and 
CypD-/- MEFs were incubated with cycloheximide and mitoSTAT3 abundance were 
assessed from purified mitochondrial extracts. Blots are representative of 2 independent 
experiments.  (F) WT, STAT3-/- MEFs, or STAT3-/- MEFs reconstituted with STAT3 WT 
or STAT3/1S were treated with H2O2, stained with mitoSOX, and then analyzed by flow 
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cytometry. Results are normalized to each respective untreated sample. *p<0.01, 
**p<0.001, #p=0.0005.  N=5 independent experiments.    
 Figure 8: Model of mitoSTAT3 regulation.  Upon initial stimulation (left panel) 
mitoSTAT3 and/or mitochondrial proteases (mitoproteases) are post-translationally 
modified that induces their association and leads to the proteolytic cleavage of 
mitoSTAT3.  Presumably proteolytic fragments of mitoSTAT3 may be further degraded 
or may contribute to extra-mitochondrial signaling.  With continued stimulation (right 
panel) new protein synthesis (either of STAT3 or a chaperone protein required for 
STAT3 mitochondrial targeting) couples with Ser727 phosphorylation of STAT3 to 
mediate targeting of STAT3 to the mitochondria.  Likely, mitoSTAT3 is also tyrosine 
phosphorylated (pY, non-Tyr705 site). Following its import into the mitochondria, 
mitoSTAT3 is dephosphorylated by a protein tyrosine phosphatase (PTP).  This 
facilitates its interaction with CypD, which is likely important for mitoSTAT3’s proper 
folding and mitochondrial stability.  This association determines ROS abundance and is 
also likely important for other downstream effects of mitoSTAT3 including regulation of 
the ETC and maintenance of the permeability transition pore (mitoSTAT3’s actions). 
OMM, outer mitochondrial membrane, IMS, intermembrane space, IMM, inner 
mitochondrial membrane.         
 








